CL2012002285A1 - Forma cristalina del 4-{(1s,2s)-2-[((r)-4-ciclobutil-2-metilpiperazin-1-il)carbonil]cicclopropil]benzamida; composicion farmaceutica, y su uso para el tratar esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastorno cognitivo asociado con esquizonfrenia. - Google Patents
Forma cristalina del 4-{(1s,2s)-2-[((r)-4-ciclobutil-2-metilpiperazin-1-il)carbonil]cicclopropil]benzamida; composicion farmaceutica, y su uso para el tratar esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastorno cognitivo asociado con esquizonfrenia.Info
- Publication number
- CL2012002285A1 CL2012002285A1 CL2012002285A CL2012002285A CL2012002285A1 CL 2012002285 A1 CL2012002285 A1 CL 2012002285A1 CL 2012002285 A CL2012002285 A CL 2012002285A CL 2012002285 A CL2012002285 A CL 2012002285A CL 2012002285 A1 CL2012002285 A1 CL 2012002285A1
- Authority
- CL
- Chile
- Prior art keywords
- narcolepsy
- methylpiperazin
- benzamide
- obesity
- cyclobutyl
- Prior art date
Links
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 206010041349 Somnolence Diseases 0.000 title abstract 2
- 201000003631 narcolepsy Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000000980 schizophrenia Diseases 0.000 title abstract 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
- -1 (r) -4-cyclobutyl-2-methylpiperazin-1-yl Chemical group 0.000 title 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 title 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30558110P | 2010-02-18 | 2010-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012002285A1 true CL2012002285A1 (es) | 2013-01-25 |
Family
ID=44370079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012002285A CL2012002285A1 (es) | 2010-02-18 | 2012-08-17 | Forma cristalina del 4-{(1s,2s)-2-[((r)-4-ciclobutil-2-metilpiperazin-1-il)carbonil]cicclopropil]benzamida; composicion farmaceutica, y su uso para el tratar esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastorno cognitivo asociado con esquizonfrenia. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20110201622A1 (https=) |
| EP (1) | EP2536701A4 (https=) |
| JP (1) | JP5746718B2 (https=) |
| KR (1) | KR20130034009A (https=) |
| CN (1) | CN103140481A (https=) |
| AR (1) | AR080203A1 (https=) |
| AU (1) | AU2011218490B9 (https=) |
| BR (1) | BR112012020780A2 (https=) |
| CA (1) | CA2789884A1 (https=) |
| CL (1) | CL2012002285A1 (https=) |
| IL (1) | IL221430A0 (https=) |
| MX (1) | MX2012009537A (https=) |
| NZ (1) | NZ602108A (https=) |
| RU (1) | RU2012136921A (https=) |
| SG (1) | SG183231A1 (https=) |
| TW (1) | TW201136898A (https=) |
| WO (1) | WO2011102793A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2195293T3 (da) | 2007-08-22 | 2014-02-03 | Astrazeneca Ab | Cyclopropylamidderivater |
| TW201039825A (en) * | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| BR112012020629A2 (pt) | 2010-02-18 | 2018-06-19 | Astrazeneca Ab | forma cristalina, e, método para a terapia de um distúrbio |
| CN109438423A (zh) * | 2018-09-12 | 2019-03-08 | 通化师范学院 | 一种肺癌靶向化合物azd-3759的合成工艺的新方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (https=) * | 1963-04-04 | 1900-01-01 | ||
| US3449427A (en) * | 1965-06-03 | 1969-06-10 | Smithkline Corp | Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes |
| US3697506A (en) * | 1970-08-07 | 1972-10-10 | Pfizer | Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor |
| US3686335A (en) * | 1970-12-21 | 1972-08-22 | Smith Kline French Lab | 5-vinyl-5h-di benzo(a,d)cycloheptenes |
| US4432987A (en) * | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
| DE69013131T2 (de) * | 1989-12-29 | 1995-05-24 | Banyu Pharma Co Ltd | 2-(2-Cyclopropylpyrrolidin-4-ylthio)carbapenemderivate. |
| DE4131139A1 (de) * | 1991-09-19 | 1993-03-25 | Bayer Ag | Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure |
| KR100296810B1 (ko) * | 1993-03-12 | 2001-10-24 | 로렌스 티. 마이젠헬더 | 결정성세프티오퍼유리산 |
| EP1090919A4 (en) * | 1998-06-26 | 2002-05-22 | Chugai Pharmaceutical Co Ltd | FINE POWDER OF L-ALPHA-AMINOADIPIC ACID DERIVATIVES, SOLID PREPARATIONS FOR ORAL USE AND A METHOD FOR TREATING Loose POWDER |
| US6284761B1 (en) * | 1999-01-08 | 2001-09-04 | Neurogen Corporation | 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands |
| EP1248869A2 (en) * | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| US6521619B2 (en) * | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
| PL364625A1 (en) * | 2001-02-23 | 2004-12-13 | Merck & Co, Inc. | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
| WO2003026572A2 (en) * | 2001-09-26 | 2003-04-03 | Merck & Co., Inc. | Crystalline forms of ertapenem sodium |
| US6861432B2 (en) * | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| JP2005526800A (ja) * | 2002-03-22 | 2005-09-08 | エルジー・ライフ・サイエンシーズ・リミテッド | （２Ｓ）−Ｎ−５−［アミノ（イミノ）メチル］−２−チエニルメチル−１−（２Ｒ）−２−［（カルボキシルメチル）アミノ］−３，３−ジフェニルプロパノイル−２−ピロリジンカルボキサミド・ｎＨ２Ｏの新しい結晶形 |
| US20040077618A1 (en) * | 2002-10-22 | 2004-04-22 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
| US20040209858A1 (en) * | 2002-10-22 | 2004-10-21 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
| CA2523431A1 (en) * | 2003-04-23 | 2004-11-25 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
| TWI339206B (en) * | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| SI1948607T1 (sl) * | 2005-09-16 | 2010-07-30 | Janssen Pharmaceutica Nv | Ciklopropil amini kot modulatorji histaminskega H3 receptorja |
| RU2008132966A (ru) * | 2006-01-13 | 2010-02-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные циклогексилпиперазинилметанона и их применение в качестве модуляторов гистамин н3 рецептора |
| BRPI0712823A2 (pt) * | 2006-06-23 | 2012-07-24 | Abbott Lab | derivados de ciclopropil amina como moduladores de receptor de histamina h3 |
| US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| TW200828371A (en) * | 2006-09-21 | 2008-07-01 | Matsushita Electric Industrial Co Ltd | Chip-type filter |
| DK2195293T3 (da) * | 2007-08-22 | 2014-02-03 | Astrazeneca Ab | Cyclopropylamidderivater |
| ES2460897T3 (es) * | 2007-10-04 | 2014-05-14 | F. Hoffmann-La Roche Ag | Derivados de ciclopropil aril amida y usos de los mismos |
| TW200934772A (en) * | 2008-01-15 | 2009-08-16 | Lilly Co Eli | Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide |
| TW201039825A (en) * | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| BR112012020629A2 (pt) * | 2010-02-18 | 2018-06-19 | Astrazeneca Ab | forma cristalina, e, método para a terapia de um distúrbio |
-
2011
- 2011-02-17 US US13/029,351 patent/US20110201622A1/en not_active Abandoned
- 2011-02-17 NZ NZ602108A patent/NZ602108A/en not_active IP Right Cessation
- 2011-02-17 MX MX2012009537A patent/MX2012009537A/es not_active Application Discontinuation
- 2011-02-17 JP JP2012553848A patent/JP5746718B2/ja not_active Expired - Fee Related
- 2011-02-17 KR KR1020127024173A patent/KR20130034009A/ko not_active Withdrawn
- 2011-02-17 BR BR112012020780A patent/BR112012020780A2/pt not_active IP Right Cessation
- 2011-02-17 CA CA2789884A patent/CA2789884A1/en not_active Abandoned
- 2011-02-17 TW TW100105298A patent/TW201136898A/zh unknown
- 2011-02-17 AR ARP110100484A patent/AR080203A1/es unknown
- 2011-02-17 RU RU2012136921/04A patent/RU2012136921A/ru not_active Application Discontinuation
- 2011-02-17 AU AU2011218490A patent/AU2011218490B9/en not_active Ceased
- 2011-02-17 WO PCT/SE2011/050170 patent/WO2011102793A1/en not_active Ceased
- 2011-02-17 SG SG2012058848A patent/SG183231A1/en unknown
- 2011-02-17 CN CN201180019676XA patent/CN103140481A/zh active Pending
- 2011-02-17 EP EP20110744973 patent/EP2536701A4/en not_active Withdrawn
-
2012
- 2012-08-13 IL IL221430A patent/IL221430A0/en unknown
- 2012-08-17 CL CL2012002285A patent/CL2012002285A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012020780A2 (pt) | 2016-05-03 |
| RU2012136921A (ru) | 2014-03-27 |
| MX2012009537A (es) | 2012-08-31 |
| NZ602108A (en) | 2014-09-26 |
| AU2011218490A1 (en) | 2012-10-04 |
| CN103140481A (zh) | 2013-06-05 |
| AU2011218490B2 (en) | 2014-11-13 |
| AU2011218490B9 (en) | 2014-12-18 |
| SG183231A1 (en) | 2012-09-27 |
| IL221430A0 (en) | 2012-10-31 |
| CA2789884A1 (en) | 2011-08-25 |
| JP2013520412A (ja) | 2013-06-06 |
| EP2536701A4 (en) | 2014-05-07 |
| JP5746718B2 (ja) | 2015-07-08 |
| TW201136898A (en) | 2011-11-01 |
| WO2011102793A1 (en) | 2011-08-25 |
| AR080203A1 (es) | 2012-03-21 |
| KR20130034009A (ko) | 2013-04-04 |
| EP2536701A1 (en) | 2012-12-26 |
| US20110201622A1 (en) | 2011-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201400033A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| CL2014002334A1 (es) | Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras. | |
| CL2012002259A1 (es) | Forma cristalina de 4-{(1s,2s)-2-[84-ciclobutilpiperazin-1-il-carbonil]ciclopropil}benzamida; composicion farmacéutica; y su uso para tratar enfermedades tales como esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastornos por deficit de atencion con hiperactividad, dolor, entre otras. | |
| CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
| MX386598B (es) | Compuestos antibacterianos. | |
| IN2015DN00335A (https=) | ||
| CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
| CL2008001921A1 (es) | Compuestos derivados de heterociclos sustituidos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ictus, isquemia cerebral, alzheimer, dolor, entre otras. | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| CR20150500A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril- aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| CL2010001159A1 (es) | Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros. | |
| CR20150448A (es) | Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos | |
| CL2011000668A1 (es) | Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras. | |
| BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
| CL2013001073A1 (es) | Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras. | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции | |
| PH12015500746A1 (en) | Benzamides | |
| MX2014008706A (es) | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. | |
| CL2012002540A1 (es) | Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras. | |
| CL2013000756A1 (es) | Forma cristalaina del citrato diacido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano; proceso de preparacion; composicion farmaceutica; y su uso para tratar o prevenir un trastorno de la memoria, un trastorno cognitivo, neurodegeneracion, entre otros. | |
| BR112015013675A2 (pt) | composições compreendendo vortioxetina e donepezil | |
| MX2016006633A (es) | Uso de hidroxamatos de indolilo e indolinilo para tratar trastornos neurodegenerativos o deficiencias cognitivas. | |
| UY32837A (es) | Uso de la 4-aminopiridina para mejorar el deterioro cognitivo en pacientes con desmielinizacion y otros estados del sistema nervioso |